Document dMR2eDYVyaR3XzmYoR4jE6DB

To: Scr From: Sent: Subject: Received: 5.1.2e 512s 5.1.2e 512 @rivm.nl] @chemours.com; restrictiePFAS [AZ @rivm. ni] Thur 7/28/2022 1:31:47 PM [EXE RE: [EXT] RE: Email for clarification on PFAS uses and emission data Thur 7/28/2022 1:31:57 PM 2965849 Thnx! [EXER <BNCEEC From: Sent: Thursday, July 28, 2022 3:25 PM or ivm.nl> To: 5.1.2e s12e @chemours.com> Cc: 5.1.2e @chemours.com>; restrictiePFAS ivm.nl> JE Subject: [EXT] RE: Email for clarification on PFAS uses and emission data [External [EEE email. Confirm links and attachments before opening. DearRES | showed these figures as an illustration on our progress for the different use levels. As indicated they are preliminary results. In the restriction dossier we will clearly describe our finding regarding tonnages and emissions for the different use sectors; also specified for different PFAS subgroups. Of course, in our report proper definitions and references should be included. Kind regards, Centre for Safety of Substances and Products National Institute for Public Health and the Environment Antonie van Leeuwenhoeklaan 9 | 3721 MA Bilthoven PO Box 1 (posthak 1) | 3720 BA Bilthoven | The Netherlands M e-mail rivm.nl Committed to health and sustainability vwFrom: REO <A W-L @ chemours.com> Sent: donderdag 28 juli 2022 15:07 @ rivm.nl> @chemours.com> Subject: FW: Email for Importance: High clarification on PFAS uses and emission data A colleague of ow: was present at the FPP4EU conference in June. | was alerted also in your Chemcon presentation): the Thermal & Specialized Solutions business (F-gases), by him about the 2 slides below that you used (I believe they were PFAS used in EU eev-- ergy ------------ b br wey EE hESSH - * 2965849 transport Bowie (TURAL) PFAS emission in EU MVACR ge ---- PFAS production Medical Appbcation Tramportation $d rwatment | Coumtich Rk Petrchr miu nin ng Among the content presented, these slides illustrate the overview on the PFAS uses and the PFAS emissions on which we would like to get additional information. We are aware that the data presented are still preliminary results, but we would like to address you a set of questions to better understand and interpret the information you showed: 1. What is the source of the data presented for both uses and emissions? (e.g., answers to consultations, call for evidence reports...) wn . What are the absolute values presented for both tonnage of use and emissions data? . What applications do the "Transport"/" Transportation" and "Medical Devices" /"Medical Application" categories include? . What is the split among applications under the figure "Gaseous PFAS"? . The F-gases in scope depends on the PFAS definition used for the data presented. What definition was used? aus. Some F-gases quickly degrade once emitted and are not persistent. Some of them partly degrade to other PFASs. wekien into account and if yes, how were they considered in the split among Gaseous and non-gaseous PFAS? Was this We look forward to receiving your input and we remain at your disposal for any further clarification you might need. Kind regards, M: Chemours Netherlands B.V. Baanhoekweg 22 3313 LA Dordrecht < Chemoure" See ourweb page at h www. chemours.com for a full directory of Chemours sites, staff, services and career opportunities. This communicationis for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. if you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as" E-Contract wl 965849 mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for of transfers data to third parties. Chemours Netherlands B.V. Baanhoekweg 22 3313 LA Dordrecht Statutaire zetel: Dordrecht Dossiernummer: 54013445 This communication is for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e-mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties. https://www _chemours.com/en/email-disclaimer Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent ofdit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico'sverbonden aan het elektronisch verzenden van berichten. www. rivin.nl De Zorg voor morgen begint vandaag This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete no the message. RIVM accepts liability for damage of any kind resulting from the risks inherent in the electronic transmission ofmessages. www.rivim.nl`en Committed to health and sustainability Chemours Netherlands B.V. Baanhoekweg 22 3313 LA Dordrecht Statutaire zetel: Dordrecht Dossiernummer: 54013445 This communication is for use by the intended recipient and contains information that may be privileged, confidential or copyrighted under applicable law. If you are not the intended recipient, you are hereby formally notified that any use, copying or distribution of this e-mail, in whole or in part, is strictly prohibited. Please notify the sender by return e-mail and delete this e-mail from your system. Unless explicitly and conspicuously designated as "E-Contract Intended", this e- mail does not constitute a contract offer, a contract amendment, or an acceptance of a contract offer. This e-mail does not constitute a consent to the use of sender's contact information for direct marketing purposes or for transfers of data to third parties. https://www.chemours.com/en/email-disclaimer